Table 1.
Clinical characteristics of 76 patients with gastric cancer
| Variable | No. of patients |
|---|---|
| Gender (male/female) | 47/29 |
| Age (years; median, range) | 56, 31–82 |
| CEA (U/L; < 5/≥5) | 54/22 |
| Tumor size (cm; < 5/≥5) | 47/29 |
| H.pylori antibody (positive/negative) | 41/35 |
| Histological type (differentiated/undifferentiated) | 17/59 |
| Lymphatic invasion (absent/present) | 18/58 |
| Vascular invasion (absent/present) | 66/10 |
| Tumor (T) invasion (T1 + T2/T3 + T4) | 24/52 |
| Lymphoid nodal (N) status (N0 + N1/N2 + N3) | 35/41 |
| Distant metastasis (M) status (M0/M1) | 72/4 |
| TNM stage (I + II/III + IV) | 25/51 |
| CD4+IL-22+ T-cell percentage (median, range)a | 2.4, 0.2–8.2 |
| Th22-cell percentage (median, range)b | 1.1, 0.3–2.3 |
CEA carcinoembryonic antigen
aCD4+IL-22+ T-cell percentage was acquired on CD4+IL-22+cells in CD4+ T cells that gated on CD3+CD4+ cells of tumor tissues
bTh22-cell percentage was acquired on CD4+IL-22+IL-17−IFN-γ−cells in CD4+ T cells that gated on CD3+CD4+ cells of tumor tissues